Chin-Tan-Min_2

CHIN Tan Min

Dr Chin is a medical oncologist with a clinical interest in thoracic oncology, especially non-smoking related non-small cell lung cancers (NSCLC). Her research interest lies in EGFR mutant NSCLC, and she has conducted both bench, as well as translational and clinical studies in this area.

csictm@nus.edu.sg

Biosketch

Principal Associate, Cancer Science Institute

Year(s) Degree (if applicable) Institute
1997 MBBS National University of Singapore
2002 MRCP (UK) Royal College of Physicians
2013 – present Principle Associate, Cancer Science Institute of Singapore, NUS
2008 – present Consultant, Dept of Hematology-Oncology, NCIS
2006 – 2007 Research Fellow, Massachusetts General Hospital

Research

Dr Chin is a medical oncologist with a clinical interest in thoracic oncology, especially non-smoking related non-small cell lung cancers (NSCLC). Her research interest lies in EGFR mutant NSCLC, and she has conducted both bench, as well as translational and clinical studies in this area. Her research is mainly focused on two areas- the first, pathogenesis of EGFR mutant cancers, given its predisposition in Asian non-smoking women. We are studying if hormonal influence may play a role in the pathogenesis of these cancers. The second focus of research is in optimizing treatment of EGFR mutant cancers, and delaying/ reversing the acquisition of acquired resistance to EGFR tyrosine kinase inhibitors.

In collaboration with Massachusetts General Hospital, we have conducted a clinical trial of treating NSCLC patients with sensitizing EGFR mutations with Gefitinib and Hydroxychloroquine, to determine if the progression free survival on Gefitinib can be prolonged. The phase II study has now completed accrual, and biomarkers that may predict response and resistance are currently being studied. Our preliminary studies show that circulating free tumor DNA can be detected in the blood of these patients, and serial blood studies of patients on EGFR TKI therapy may provide useful information about clinical response and progression. Bench studies are also focused on elucidating mechanisms of acquired resistance to EGFR TKI in NSCLC.